FBR & Co Comments on Supernus Pharmaceuticals, Inc.’s FY2019 Earnings (SUPN)
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Stock analysts at FBR & Co issued their FY2019 earnings per share (EPS) estimates for Supernus Pharmaceuticals in a note issued to investors on Monday. FBR & Co analyst D. Buck forecasts that the specialty pharmaceutical company will post earnings per share of $2.35 for the year. FBR & Co has a “Buy” rating and a $53.00 price objective on the stock. FBR & Co also issued estimates for Supernus Pharmaceuticals’ FY2020 earnings at $3.25 EPS.
Several other analysts have also issued reports on SUPN. Jefferies Group LLC upped their price objective on Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Thursday, July 13th. Janney Montgomery Scott started coverage on Supernus Pharmaceuticals in a research note on Friday, July 14th. They issued a “neutral” rating and a $47.00 price objective on the stock. Finally, Piper Jaffray Companies lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price objective on the stock. in a research note on Monday, July 17th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $48.38.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/24/fbr-co-comments-on-supernus-pharmaceuticals-inc-s-fy2019-earnings-supn.html.
Supernus Pharmaceuticals (NASDAQ SUPN) traded up 0.72% during mid-day trading on Tuesday, reaching $41.70. The company’s stock had a trading volume of 196,643 shares. The company has a 50 day moving average of $42.67 and a 200-day moving average of $39.92. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.04. The stock has a market cap of $2.11 billion, a PE ratio of 21.04 and a beta of 1.30.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%.
In other news, insider Stefan K.F. Schwabe sold 95,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total value of $167,758.07. Following the transaction, the vice president now owns 17,500 shares in the company, valued at approximately $791,525. The disclosure for this sale can be found here. In the last quarter, insiders have sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. BlackRock Inc. increased its stake in shares of Supernus Pharmaceuticals by 156,173.3% during the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after purchasing an additional 6,692,025 shares during the period. Vanguard Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 39.1% during the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the period. Emerald Advisers Inc. PA bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $21,474,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $17,553,000. Finally, Hodges Capital Management Inc. bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $17,220,000. Institutional investors own 94.71% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.